multi target TKI

Apitolisib - Axitinib - Cabozantinib - Dovitinib - Pazopanib - Sorafenib - Sunitinib - Tivozanib      

Select            
Trial Studied trt Control trt patientstagsROB Trial result

advanced breast cancer (metastatic)

lapatinib
Johnston (EGF30008) , 2009      NCTlapatinib + letrozoleletrozole alone HR positive Low risk of bias conclusive
Di Leo, 2008        NCTlapatinib + paclitaxelpaclitaxel alone 1st line Low risk of bias negative
sorafenib
Baselga, 2012     sorafenib + capecitabinecapecitabine alone HER-2 negative Low risk of bias suggesting
Schwartzberg, 2013      NCTsorafenib + gemcitabine or capecitabinegemcitabine or capecitabine alone 2nd line HER-2 negative Exploratory suggesting
Gradishar, 2013     sorafenib + paclitaxelpaclitaxel alone 1st line HER-2 negative Low risk of bias negative

renal-cell carcinoma (advanced)

apitolisib
Powles, 2014   apitolisibeverolimus -
axitinib
AXIS (Rini), 2011      NCTaxitinibsorafenibsuggesting
Qin, 2012   axitinibsorafenib -
cabozantinib
METEOR, 2015    NCTcabozantinibeverolimus after VEGFR-targeted therapy failure 2nd line Risk of bias suggesting
CABOSUN, 2017      NCTcabozantinibsunitinibfirst-line therapy in patients with intermediate- or poor-risk 1st line Exploratory suggesting
dovitinib
GOLD      NCTdovitinibsorafenibRisk of bias negative
pazopanib
Sternberg, 2010     pazopanibplaceboLow risk of bias suggesting
VEG105192, 2010        NCTpazopanibplacebosuggesting
COMPARZ, 2013      NCTpazopanibsunitinibnegative
sorafenib
Escudier, 2009     sorafenibinterferon alphaExploratory negative
TARGET, 2007          NCTsorafenibplaceboLow risk of bias suggesting
Ratain, 2006     sorafenibplaceboExploratory -
sunitinib
Motzer, 2007          NCTsunitinibinterferon alphasuggesting
SWITCH      NCTsunitinibsorafenib -
tivozanib
TIVO-1, 2013      NCTtivozanibsorafenibsuggesting